Education
About Us
Working with TipRanks
Follow Us
Kyowa Kirin Co Ltd (JP:4151)
:4151
4151 Stock Chart & Stats
¥2585.50
-¥17.50(-0.75%)
At close: 4:00 PM EST
¥2585.50
-¥17.50(-0.75%)
Day’s Range― - ―
52-Week Range¥2,034.00 - ¥2,912.00
Previous CloseN/A
Volume778.60K
Average Volume (3M)1.20M
Market Cap
¥1.43T
Enterprise Value¥949.13B
Total Cash (Recent Filing)¥218.77B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)21.3
Beta0.33
Next Earnings
May 12, 2026EPS Estimate
28.74Next Dividend Ex-DateN/A
Dividend Yield2.33%
Share Statistics
EPS (TTM)65.79
Shares Outstanding525,634,500
10 Day Avg. Volume1,064,410
30 Day Avg. Volume1,199,913
Financial Highlights & Ratios
PEG Ratio1.49
Price to Book (P/B)1.48
Price to Sales (P/S)2.66
P/FCF Ratio22.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,025.00Price Target Upside-21.68% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)139.17
Revenue Forecast (FY)¥515.47B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetAn almost debt-free balance sheet and rising equity provide durable financial resilience, lowering default risk and preserving flexibility to fund R&D, acquisitions or label-expansions from internal resources. Low leverage supports long-term stability even through cyclical industry stress.
Sustained Revenue GrowthConsistent top-line growth across 2020–2025 signals healthy commercial traction in core areas (oncology, nephrology, immunology). Durable revenue expansion underpins reinvestment in pipeline, scale benefits for manufacturing and commercialization, and stronger bargaining with partners over time.
High Gross Margins & Improving FCFVery high gross margins indicate structural product pricing and biologics competitiveness, while the step-up in free cash flow in 2025 shows improving cash generation. Together these support sustainable reinvestment in R&D and funding of strategic initiatives without heavy financing.
Bears Say
Earnings Margin VolatilityMeaningful swings in net margin reduce predictability of long-term profitability and complicate capital allocation. Persistent variability can reflect product-mix shifts, one-offs, or pricing/reimbursement pressures that may constrain sustainable return generation and investor visibility over months.
Inconsistent Cash Flow ConversionVariable conversion of accounting profits into free cash flow creates uncertainty in funding cycles for R&D, commercialization and dividends. This inconsistency raises the likelihood of occasional external financing needs or delayed investments, weakening operational predictability over the medium term.
Amgen Collaboration TerminationRegaining full control of rocatinlimab shifts regulatory, development and commercial burden to Kyowa Kirin and removes partner risk-sharing and likely milestone streams. Even with Amgen manufacturing, the move raises execution, funding and commercialization risks that could strain resources and timelines.
Kyowa Kirin Co News
4151 FAQ
What was Kyowa Kirin Co Ltd’s price range in the past 12 months?
Kyowa Kirin Co Ltd lowest stock price was ¥2034.00 and its highest was ¥2912.00 in the past 12 months.
What is Kyowa Kirin Co Ltd’s market cap?
Kyowa Kirin Co Ltd’s market cap is ¥1.43T.
When is Kyowa Kirin Co Ltd’s upcoming earnings report date?
Kyowa Kirin Co Ltd’s upcoming earnings report date is May 12, 2026 which is in 68 days.
How were Kyowa Kirin Co Ltd’s earnings last quarter?
Kyowa Kirin Co Ltd released its earnings results on Feb 09, 2026. The company reported ¥65.79 earnings per share for the quarter, beating the consensus estimate of ¥40.884 by ¥24.906.
Is Kyowa Kirin Co Ltd overvalued?
According to Wall Street analysts Kyowa Kirin Co Ltd’s price is currently Overvalued.
Does Kyowa Kirin Co Ltd pay dividends?
Kyowa Kirin Co Ltd pays a Semiannually dividend of ¥30 which represents an annual dividend yield of 2.33%. See more information on Kyowa Kirin Co Ltd dividends here
What is Kyowa Kirin Co Ltd’s EPS estimate?
Kyowa Kirin Co Ltd’s EPS estimate is 28.74.
How many shares outstanding does Kyowa Kirin Co Ltd have?
Kyowa Kirin Co Ltd has 525,634,500 shares outstanding.
What happened to Kyowa Kirin Co Ltd’s price movement after its last earnings report?
Kyowa Kirin Co Ltd reported an EPS of ¥65.79 in its last earnings report, beating expectations of ¥40.884. Following the earnings report the stock price went down -1.353%.
Which hedge fund is a major shareholder of Kyowa Kirin Co Ltd?
Currently, no hedge funds are holding shares in JP:4151
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kyowa Kirin Co Ltd
Kyowa Kirin Co., Ltd. is a global biotechnology company based in Japan, focusing on the research, development, manufacturing, and marketing of pharmaceuticals. The company operates primarily in the fields of oncology, nephrology, and immunology, and is known for its innovative therapeutic solutions, including monoclonal antibodies and other biopharmaceuticals. Kyowa Kirin aims to contribute to the advancement of healthcare through the development of breakthrough medicines that address unmet medical needs.
4151 Stock 12 Month Forecast
Average Price Target
¥2,025.00
▼(-21.68% Downside)
Technical Analysis
Astellas Pharma
―
Chugai Pharmaceutical Co
―
Daiichi Sankyo Company
―
Eisai Co
―
ONO Pharmaceutical Co
―
Options Prices
Currently, No data available
---